Mark Tuttle, MD
Interventional Cardiology · Greeley, CONPI 1194086900
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (52.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Medtronic accounts for 74.5% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2020 at $21,254 and has fallen 94.7% since, to $1,129 in 2025.
Across 174 payments — averaging $231.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$30K
- Abbott$4K
- Edwards Lifesciences$3K
- Abiomed$2K
- Boston Scientific$739
- Shockwave Medical, Inc$200
- plus $685 from 12 others
Across 3 payments — averaging $13,469 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Edwards Lifesciences$40K
- Medtronic$800
What the payments were for
- Consulting fees$4,31311%
- Speaking & faculty fees$2,0005%
- Grants$21,00052%
- Travel & lodging$5,37113%
- Food & beverage$7,19618%
- Education$3351%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 53 | $29,969 |
| Abbott | 31 | $3,682 |
| Edwards Lifesciences | 43 | $3,253 |
| Abiomed | 10 | $1,687 |
| Boston Scientific | 12 | $739 |
| Shockwave Medical, Inc | 4 | $200 |
| Philips North America LLC | 4 | $141 |
| Johnson & Johnson | 2 | $122 |
| Amgen | 2 | $106 |
| Cardiva Medical, Inc. | 2 | $78 |
| W. L. Gore & Associates, Inc. | 2 | $42 |
| Cardiovascular Systems Inc. | 2 | $41 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $36 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Terumo Medical Corporation | 1 | $30 |
| Novartis | 1 | $20 |
| Avanos Medical | 1 | $18 |
| Chiesi USA, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$7,317
- Impella$1,572
- Xience V coronary stent system$1,478
- EVOQUE$1,375
- TRICLIP$593
- WATCHMAN Access System$385
- AMPLATZER PICCOLO$355
- Omnilink Elite vascular stent system$219
- HeartMate 3 Left Ventricular Dev$195
- 3F$142
- Integrity$140
- Watchman$124
- AMPLATZER$123
- CARDIOMEMS$112
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$107
- XARELTO$107
How this compares
$40,215 in reported general payments places this provider in the 80th percentile of 111 interventional cardiology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 46 | $56,767 |
| Repatha SureclickEvolocumab | 17 | $15,487 |
| XareltoRivaroxaban | 14 | $10,956 |
| Metoprolol Succinate | 107 | $1,625 |
| ClopidogrelClopidogrel Bisulfate | 84 | $1,330 |
| Atorvastatin Calcium | 112 | $1,270 |
| Ezetimibe | 30 | $1,172 |
| Rosuvastatin Calcium | 49 | $712 |
| Warfarin Sodium | 14 | $472 |
| Losartan Potassium | 50 | $415 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 13 | $387 |
| Carvedilol | 22 | $360 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 13 | $339 |
| Chlorthalidone | 11 | $283 |
| Furosemide | 57 | $276 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $122 | $10,95614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 111 interventional cardiology providers in Colorado.
Other interventional cardiology in Greeley
- Michael KimGreeley$24K
- Ehrin ArmstrongEnglewood$718K
- Gareth MorganAurora$536K
- Jamaluddin MolooAurora$272K
- Jenny Zablah AlabiAurora$269K
- Srinivas IyengarBoulder$254K
- Nima AghiliLakewood$220K
- Sridhar Sampath-KumarAurora$142K
- Matthew ZipseAurora$137K
- Jeffrey ParkAurora$132K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.